Biogen Reports observational Data for Pembrolizumab in Diffuse large B-cell lymphoma

Biogen today announced observational results for pembrolizumab in patients with diffuse large B-cell lymphoma. The study demonstrated that pembrolizumab improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of diffuse large B-cell lymphoma and support the continued development of pembrolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.